Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Herpes simplex virus and application thereof

A technology of herpes simplex virus and virus strain, applied in the direction of virus, virus/bacteriophage, double-stranded DNA virus, etc., to achieve the effect of enhancing replication and killing ability

Active Publication Date: 2020-04-10
BEIJING WELLGENE CO LTD
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these viruses can enter cells to deliver genes, they need to be

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Herpes simplex virus and application thereof
  • Herpes simplex virus and application thereof
  • Herpes simplex virus and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106] Example 1 Obtaining of HL-1 strain virus with oncolytic effect

[0107] a) Virus collection

[0108] 63 healthy volunteers with recurrent herpes labialis were recruited, and the herpes fluid was aseptically collected.

[0109] b) Virus screening

[0110] The purpose of this section is to test and screen primary clinical isolates of HSV-1 and select the virus strain with the strongest oncolytic ability.

[0111] Experiments were performed simultaneously using 5 to 8 virus strains each time. Using 17 strains of HSV-1 virus as a control, the virus strains were infected with the same MOI in cells in a six-well plate, and parallel experiments were performed, and the CPE (cytopathic effect) phenomenon caused by the virus was observed after 48 hours of infection and evaluated after crystal violet staining. number of plaques. CPE should be caused by typical HSV-1 infection. The cells become round and gradually fall off from the center of infection to form plaques. Strains ...

Embodiment 2

[0126] Example 2 Comparison of oncolytic effects between HL-1 wild strain and 17 strains

[0127] This example provides the comparative experiments and results of replication of HL-1 and 17 strains on different cells and their ability to transfect tumor cells. Experimental cells include: Hep G2 human liver cancer cells, A375 human skin cancer cells, A549 human lung cancer cells, MCF7 human breast cancer cells, HeLa human cervical cancer cells, U251 human glioma cells, and Vero monkey kidney cells.

[0128] The experimental method is as follows:

[0129] 1. Microscopic observation after HL-1 and HSV (17) transfected different cells respectively

[0130] The above-mentioned cells in the logarithmic growth phase were taken, digested and subcultured into a six-well plate for culture. After 24 hours, the old medium was discarded, and 2ml of medium was added to each well. The transfection was carried out according to the number of viruses at different MOIs. After the virus was a...

Embodiment 3

[0154] Example 3 Comparison of Oncolytic Effects of HSV (HL-1) Recombinant Virus and HSV (17) Recombinant Virus

[0155] The ICP34.5 gene and ICP47 gene of the virus strain with the CCTCC preservation number V201810 (CCTCC: 201810) of the present invention and the control virus 17 virus strain were knocked out by genetic engineering methods, and the recombinant virus HL1-△34.5- after gene knockout was compared. △47 and 17-△34.5-△47 have different transfection ability to tumor cells. Experimental cells include Hep G2 human liver cancer cells, A375 human skin cancer cells, A549 human lung cancer cells, MCF7 human breast cancer cells, HeLa human cervical cancer cells, U251 human glioma cells, and Vero monkey kidney cells.

[0156] Cells in the logarithmic growth phase were taken, digested and passaged to 96-well plates. After 24 hours, the old medium was discarded, and 9 different virus dilutions were added, 100 μl / well, so that the MOI was 20, 5, 1.25, 0.3125, 0.0781, 0.0195, 0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a herpes simplex virus type 1, which is a virus strain with an accession number of CCTCC NO. V201810, and an attenuated strain or a progeny culture thereof. The invention alsorelates to a composition containing the herpes simplex virus and a host cell infected by the herpes simplex virus.

Description

technical field [0001] The present invention relates to a herpes simplex virus, in particular to a non-laboratory strain of the herpes simplex virus. Compared with the laboratory virus strain, the non-laboratory virus strain of the present invention has enhanced oncolytic ability and / or gene delivery ability. Background technique [0002] Herpes Simplex Virus (HSV) belongs to the Herpesviridae family and is an enveloped double-stranded DNA virus, including two subtypes, type I (HSV-1) and type II (HSV-2). [0003] Herpes simplex virus consists of four parts: core, capsid, interlayer protein and envelope. The viral core consists of thick double-stranded DNA wound up into a filamentous scroll. The capsid surrounded by DNA has an icosahedral structure with a diameter of 100-110 nm and consists of 162 capsomers. The outside of the capsid is covered by irregularly arranged and amorphous interlayer proteins. The outermost layer of the virus is a lipid bilayer envelope with sho...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N7/00C12N15/869A61K35/763A61K48/00A61K38/20A61K38/19A61K39/395A61P35/00C12R1/93
CPCA61K35/763A61K38/193A61K38/2013A61K38/208A61K39/3955A61K48/005A61K2039/5256A61K2039/53A61P35/00C12N7/00C12N15/86C12N2710/16621C12N2710/16632C12N2710/16643C12N2800/107
Inventor 李小鹏赵婧姝周华王田田田超刘家家孙春阳
Owner BEIJING WELLGENE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com